Report workspace tools

NCT00447304COMPLETEDanonymous

Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy = ACDC-study

Sponsor

Source record

Heidelberg University

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

moxifloxacin, cholecystectomy

Indication / condition

AI-normalized

Acute Cholecystitis

Intervention

Source record

moxifloxacin, cholecystectomy

Source & freshness

Source record

NCT ID

NCT00447304

Original source

ClinicalTrials.gov

Source last updated

Jul 23, 2012

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00447304

Title

Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy = ACDC-study

Sponsor

Heidelberg University

Status

COMPLETED

Phase

PHASE3

Condition raw

Acute Cholecystitis

Condition normalized

Acute Cholecystitis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

moxifloxacin, cholecystectomy

Target normalized

moxifloxacin, cholecystectomy

Interventions

moxifloxacin, cholecystectomy

Public preview

Source record

Acute cholecystitis is frequent in the elderly, or in patients with gall stones. Most cases of severe or recurrent cholecystitis need surgery as final therapy. Today, the performed procedure in most cases for cholecystectomy in the western world is laparoscopic cholecystectomy. Only in some cases an open surgery has to be performed. Unclear is, what time point is best, concerning outcome and morbidity of the patient, immediate surgery or initial conservative therapy using antibiotics and symptomatic therapy with cholecystectomy later on. Today the performed procedure is mainly chosen by the fact, what doctor sees the patient first, surgeon or gastroenterologist. This study is performed to evaluate if one therapy is superior.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account

Create a free account first, then unlock a single report, buy credits or subscribe.